New England Biolabs (NEB), a global leader in enzyme discovery and production for molecular biology applications, has now opened its first international product development and manufacturing site in the heart of the Thames Valley’s health and life sciences (HLS) cluster.
The multi-million-pound, 30,000sqft, facility will, when fully operation from the summer 2024, enable NEB to expand its range of lyophilized reagents, which can be stored and shipped at room temperature, reducing logistical challenges. This investment represents NEB’s first product development and manufacturing site outside the USA.
The Thames Valley has one of the UK’s leading HLS clusters, and the addition of NEB only goes to highlight our growing international reputation. NEB join a deep, and proven high-quality, capability advancing R&D across many areas of HLS, including applied applications, artificial intelligence applications in healthcare, clinical trials and research and diagnostics.
Paul Britton, Chief Executive at Thames Valley Chamber of Commerce commented:
“NEB’s investment provides another example of the Thames Valley’s growing reputation, in the UK, as the leader in the Health and Life Sciences sector and our ability to attract world-class companies from around the globe. This investment is a testament to our region’s innovative ecosystem and highlights the significant foreign direct investment that continuously fuels our growth and success. We look forward to welcoming NEB to join our Thames Valley health and life sciences working group and contributing to the region’s continued growth, industry collaboration and intelligence sharing”.
